{"podcast":{"title":"Business News Today | 2 Min News | The Daily News Now!","slug":"business-finance-news-today-2-min-news-the-daily-news-now-7726192","podcast_index_feed_id":7726192,"rss_url":"https://feeds.fastcast.ai/the-daily-news-now-business.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/cover/a77b5c94-431e-4490-8653-1f676f1da586.png","author":"The Daily News Now!","episode_count":1320,"summary":"Hosted by Corey with the Story. Stay informed with the latest business, stock market, and finance headlines, updates, and breaking stories delivered daily in quick, engaging episodes. Subscribe! The Daily News Now! — Every city. Every story. AI-powered. Advertise on DNN: advertise@thednn.ai","last_synced_at":"2026-06-17T18:18:57.837082+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192"},"episode":{"title":"FCPM Sells Dyne But Watch the Milestones","slug":"fcpm-sells-dyne-but-watch-the-milestones","published_at":"2026-05-30T16:55:32+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/fcpm-sells-dyne-but-watch-the-milestones","show_page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192","url":"https://api.fastcast.ai/audio/8a101043-1c3f-4a64-98d1-6b5a68b050d5.mp3","audio_url":"https://api.fastcast.ai/audio/8a101043-1c3f-4a64-98d1-6b5a68b050d5.mp3","summary":"FCPM III Services B.V. just sold nearly 818,000 shares of Dyne Therapeutics for $14.1M — a major move that slashed their stake value by $22M — yet Dyne still anchors 11.8% of their portfolio. With Dyne’s stock up 60% in a year and a major FDA BLA for z-rostudirsen on deck for potential Q1 2027 launch, the company’s momentum is undeniable. They’re also launching a pivotal 72-week Phase III trial (FORZETTO) to confirm efficacy across mobility, lung function, and quality of life — all while advancing other therapies for rare muscular dystrophies. Investors are now watching closely: can Dyne turn regulatory wins into real-world commercial success? Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/c8d1dbdc855b99d5","meta_description":"FCPM III Services B.V. just sold nearly 818,000 shares of Dyne Therapeutics for $14.1M — a major move that slashed their stake value by $22M — yet Dyne st…","key_points":[],"chapters":[],"topics":[],"duration_seconds":130,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/fcpm-sells-dyne-but-watch-the-milestones/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/fcpm-sells-dyne-but-watch-the-milestones.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}